The Hidden Disease: A New Fight for Patients Lost in the System

FORT LEE, NJ – May 04, 2026 – For a small but significant number of people worldwide, a persistent cough, chronic eye inflammation, or recurring ear infections are not just common ailments; they are signals of a hidden, underlying genetic disorder. This condition, Plasminogen Deficiency Type 1 (PLGD-1), is so rare that most physicians will never encounter a case in their entire careers, leaving patients trapped in a years-long cycle of misdiagnosis and ineffective treatments.

On Plasminogen Deficiency Awareness Day, a concerted effort led by the biopharmaceutical company Kedrion Biopharma, in partnership with clinicians and patient advocacy groups, is shining a spotlight on this diagnostic odyssey. Through a series of global events, they aim to transform the landscape for a disease that, while rare, carries devastating consequences if left unidentified.

A Diagnostic Odyssey

PLGD-1 is an ultra-rare condition, with a published prevalence of approximately 1.6 per 1 million people. However, experts and advocates widely believe this figure is a significant underestimation. The disease is caused by a genetic inability to produce sufficient plasminogen, a protein crucial for dissolving fibrin clots. This deficiency leads to the abnormal accumulation of fibrin-rich, wood-like growths (lesions) on mucous membranes throughout the body.

These lesions can manifest in a variety of ways, often mimicking more common conditions. Ligneous conjunctivitis, a severe eye inflammation, can be mistaken for simple 'pink eye.' Growths in the respiratory tract can cause a chronic cough or airway obstruction, while lesions in the middle ear can lead to hearing loss. In some cases, the condition can impact fertility or cause recurrent infections. The potential for serious, irreversible damage—including blindness and deafness—makes a timely diagnosis critical.

Yet, a correct diagnosis is tragically elusive for most. According to the National Organization for Rare Disorders (NORD), the journey to an accurate diagnosis for patients with rare diseases takes, on average, five to seven years. "Greater awareness of conditions like PLGD-1, stronger clinician education... and earlier connections to specialists can help shorten that journey and improve quality of life for patients and families," said Pamela Gavin, CEO of NORD, in a statement highlighting the systemic challenges.

This prolonged quest for answers, often involving numerous specialists and incorrect treatments, exacts a heavy toll on patients and their families, both emotionally and financially, as they navigate a healthcare system unprepared for what it cannot easily recognize.

The Paradox of a 'Simple Test'

One of the most frustrating aspects of the PLGD-1 crisis is that a diagnosis does not require complex or prohibitively expensive technology. The condition can be identified through a straightforward laboratory blood test that measures plasminogen antigen and activity levels. Despite its availability, the test is rarely ordered.

The primary barrier is not access to the test itself, but a profound lack of awareness among frontline healthcare professionals. When a patient presents with chronic conjunctivitis, a physician's first thought is infection or allergy, not a one-in-a-million genetic disorder. Without a reason to suspect PLGD-1, the crucial test is never considered.

This gap between the existence of a diagnostic tool and its application in clinical practice is a central focus of the awareness campaign. The goal is to educate physicians to consider PLGD-1 in patients with chronic or treatment-resistant inflammatory conditions affecting mucosal surfaces. To date, fewer than 100 cases have been formally diagnosed in the United States, a number starkly at odds with prevalence estimates that suggest the true figure could be substantially higher.

"For Kedrion, Plasminogen Deficiency Awareness Day underscores the importance of collective action in addressing rare and ultra-rare disease," stated Bob Rossilli, the company's Chief Commercial Officer. "Through collaboration, we can help shorten the diagnostic journey and improve the lives of those affected by this rare disease."

An Alliance of Hope and Strategy

The fight against PLGD-1's obscurity is being waged by a powerful coalition of stakeholders. Kedrion Biopharma's leadership is complemented by the tireless work of patient advocacy organizations that provide a voice for a community long left in the shadows.

Among them is the Plasminogen Deficiency Foundation, co-founded by Dr. Rebecca Bialas, a physician and mother of two children with the condition. Her perspective bridges the professional and the deeply personal. "When your child is diagnosed with an ultra-rare disease, you quickly learn how powerful awareness can be," Dr. Bialas shared. "Seeing the PLGD-1 community gain visibility year over year gives families hope and drives real progress. Kedrion's ongoing efforts to support education and access to resources are making a meaningful difference for people who have waited far too long to be seen and supported."

This partnership reflects a growing trend in the rare disease space, where industry and advocacy align to tackle shared challenges. While advocacy groups provide grassroots support and invaluable patient insight, pharmaceutical companies bring resources, scientific expertise, and logistical power to amplify the message on a global scale.

Kedrion's commitment, however, extends beyond corporate social responsibility. The company manufactures Ryplazim, the first and only treatment specifically approved by the U.S. Food and Drug Administration (FDA) for PLGD-1. Approved in 2021, the plasma-derived therapy works by replacing the body's missing plasminogen, thereby treating the underlying cause of the lesions. This connection provides a powerful incentive for the company to identify the undiagnosed patient population. By raising awareness of the disease, Kedrion is building a pathway for patients to not only receive a name for their suffering but also to access the only targeted therapy available.

This model, where the developer of a treatment also spearheads the effort to find patients, represents a strategic evolution in the biopharmaceutical industry. It acknowledges that for ultra-rare diseases, an approved drug is of little value if the patients who need it remain undiagnosed. The campaign to elevate awareness of PLGD-1 is therefore an essential part of the therapeutic ecosystem, a necessary bridge between medical innovation and the patients it is designed to serve.